Search

Displaying results 5771 - 5780 of 10000 in total
  1. Drug

    Orbofiban

    go.drugbank.com/drugs/DB20676
    Experimental

    Orbofiban has a monoisotopic molecular weight of 361.18 Da. … The usage of the INN stem '-fiban' in the name indicates that Orbofiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist).

  2. Drug

    Gantofiban

    go.drugbank.com/drugs/DB20951
    Experimental

    Gantofiban has a monoisotopic molecular weight of 447.21 Da. … The usage of the INN stem '-fiban' in the name indicates that Gantofiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist).

  3. Drug

    Roxifiban

    go.drugbank.com/drugs/DB21089
    Experimental

    Roxifiban has a monoisotopic molecular weight of 447.21 Da. … The usage of the INN stem '-fiban' in the name indicates that Roxifiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist).

  4. Drug

    Sibrafiban

    go.drugbank.com/drugs/DB21420
    Experimental

    Sibrafiban has a monoisotopic molecular weight of 420.2 Da. … The usage of the INN stem '-fiban' in the name indicates that Sibrafiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist).

  5. Drug

    Evifacotrep

    go.drugbank.com/drugs/DB21510
    Investigational

    Evifacotrep has a monoisotopic molecular weight of 441.06 Da. … The usage of the INN stem '-cotrep' in the name indicates that Evifacotrep is a transient receptor potential canonical channel 5 (TRPC5) antagonist.

  6. Drug

    Zerencotrep

    go.drugbank.com/drugs/DB21710
    Experimental

    Zerencotrep has a monoisotopic molecular weight of 524.11 Da. … The usage of the INN stem '-cotrep' in the name indicates that Zerencotrep is a transient receptor potential canonical channel 5 (TRPC5) antagonist.

  7. Drug

    Difamilast

    go.drugbank.com/drugs/DB14987
    ApprovedInvestigational

    [L55042, A275424, A275420] As difamilast's mechanism of action involves the inhibition of PDE4, the inhibition leads to an increase in intracellular cyclic AMP and a subsequent decrease in the production … [L56052, A275420] This skin disease occurs most frequently in children and can have an onset as early as within the first 2 years of life.

  8. Drug

    Azelaic acid

    go.drugbank.com/drugs/DB00548
    ApprovedInvestigational

    Azelaic acid is a saturated dicarboxylic acid found naturally in wheat, rye, and barley. … It works in part by stopping the growth of skin bacteria that cause acne, and by keeping skin pores clear.

    Synonyms: n-nonanedioic acid
  9. Drug

    Oglufanide

    go.drugbank.com/drugs/DB05779
    Investigational

    Oglufanide was originally developed to treat severe infectious disease in Russia (where it is a registered pharmaceutical), and was extensively studied in cancer clinical trials in the United States before … being acquired by Implicit Bioscience in 2005.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Florquinitau (18F)

    go.drugbank.com/drugs/DB19215
    ApprovedInvestigational

    on PET images. … [L64052,L64053] It is the second fluorine-18 tau PET imaging agent approved in the United States, after flortaucipir (Tauvid), which was approved in 2020.[L64054,L14114]